Glomerular Diseases in Primary Care Objectives Glomerulonephritis

Glomerular Diseases in Primary Care Objectives Glomerulonephritis

11/6/2016 Objectives Glomerular Diseases in Primary Care Discuss diagnosis of glomerular diseases Sadiq Ahmed, MD, FACP, FASN Identify Nephritic and Nephrotic syndromes Associate Professor of Medicine Division of Nephrology Bone & Mineral Review clinical features, diagnosis and Metabolism treatment of glomerular emergency or RPGN University of Kentucky Glomerulonephritis Microscopic Hematuria Asymptomatic Microscopic Hematuria More than 2 RBC per HPF on a spun Nephritic Syndrome (3000 r.p.m for 5 minutes) urine Acute glomerulonephritis sediment or some prefers number of RBC more than 10,000/ml of Rapidly progressive glomerulonephritis hemocytometer chamber. Chronic glomerulonephritis Nephrotic Syndrome Nephritic Syndrome Microscopic Hematuria Glomerular origin(Dysmorphic): There is • Collection of findings associated with glomerular inflammation in proteinuria ,serum creatinine may be elevated proximity to endothelial surface with dysmorphic RBC & → Renal referral/work up for GN • Defined by hematuria, presence of dysmorphic RBCs or RBC casts on microscopic examination Non Glomerular origin(Isomorphic): →Urology • One or more of the following referral/Check upper U.tract by CT for stone, – Mild to moderate proteinuria – Mild to moderate edema neoplasm, cystic disease etc. Consider need for – Hypertension cystoscopy. – Increased creatinine – Oliguria 1 11/6/2016 Figure 25.7a Clinical differences : Nephrotic vs Nephritic Nephrotic syndrome Nephritic syndrome Proteinuria Gross >3.5GM Moderate < 3GM Serum Albumin Reduced Normal or mild reduction Hematuria Absent or trace Marked Bland urine sediment RBC cast /dysmorphic Active urine sediment Edema Marked Moderate Lipids Marked elevation Minimal elevation /normal Urine volume Normal /reduced Reduced Nephrotic Syndrome Nephritic syndrome Minimal change disease • Post infectious GN FSGS • Lupus Nephritis class II, III,IV Membranous Nephropathy • RPGN Diabetic Nephropathy • Anti‐GBM Amyloidosis • Immune complex crescentic GN • Class V Lupus Nephritis Pauci immune. ANCA + crescentic necrotizing GN • IgA nephritis & HSP • MPGN I,II,III 2 11/6/2016 Clinical Clues to Glomerular Diseases Tests for Glomerular Diseases Hematuria, Foamy urine , Elevation of Cr • CBC with diff, Renal panel, UA & Urine Protein and Creatinine • Pulmonary infection / Infiltrate / Hemoptysis Ratio • Hepatitis B, C & HIV infections • C3, C4, Ch50 • Arthralgia • ASO titre • Skin Rash • ANA, Anti Double Stranded DNA • Volume over load / new onset edema • ANCA ( C‐ANCA, P‐ANCA) • New onset Hypertension • Anti GBM Antibodies • Diseases – Endocarditis, Shunt infection, SLE, • Serum Protein Electrophoresis, Serum Protein IF, Free light chain Lymphoproliferative disorders etc assay • IVDU • Hep‐B, C and HIV RPGN Clinical presentation of RPGN Clinical condition that evolve with rapidly progressive decline in renal function and • Rapid loss of renal function characterized by an inflammatory process that • Active urinary sediment results in the formation of cellular crescents & • called crescentic glomerulonephritis. Oliguria • Hematuria/Proteinuria This is glomerular emergency. How Crescents are formed? RPGN Glomerular crescent formation is an etiologically nonspecific response to glomerular capillary rupture due to acute inflammatory injury • Rupture of GBM → spillage of inflam. mediators • Neutrophil margination • Karyorrhexis • Thrombosis • Fibrin exudation • Epithelial response 3 11/6/2016 RPGN:Case Electron microscopy of RPGN 65 YO Wmale presents to the ER with 3 weeks history of arthralgia and fatigue & URI. On exam. BP is 150/80 and there is a petechial rash visible in lower extremities and also 1+ edema. Hb is 9.4gm/dl, Creatinine 5.8mg/dl Urinalysis shows 20‐ 50 RBC/hpf & 1+ protein CxR showed bilateral infiltrate. 3 major Immunopathologic categories RPGN:Case What is the most likely cause of his renal failure? of crescentic GN • Type I A. Anti GBM disease – Anti‐GBM crescentic GN B. Lupus nephritiis • Type II C. Henoch Schoenlein – Immune complex crescentic GN purpura with crescentic • Post infectious, SLE, IgA, MPGN, Fibrillary GN D. Cryoglobulinemia • Type III E. ANCA associated – Pauci‐immune crescentic GN vasculitis – 80% ANCA positive Crescentic GN and Systemic Vasculitis ANCA test methodology • Iimmunofluroscnce technique 75% of patients with ANCA GN have some sort of – On ethanol fixed neutrophils PR3‐ANCA causes a systemic small vessel vasculitis. GPA,MPA or EGPA charecteristic cytoplasmic granular centrally accentuated immunofluroscence pattern called cANCA while MPO‐ ANCA causes a perinuclear pattern called pANCA 50‐60% patients with Anti GBM disease have • Antigen specific testing pulmonary cappillaritis – Antigen type (PR3 or MPO) is determined through antigen‐ specific methods. More specific • ELISA or capture ELISA Immune complex crescentic GN has the lowest • Bead based multiplex assay frequency of systemic vasculitis. HSP, • Appropriate paring is important for definitive DX Cryoglobulinemic GN etc. – cANCA with PR3‐ANCA & pANCA with MPO‐ANCA 4 11/6/2016 Differential Dx of ANCA disease C‐ANCA. Cytoplasmic granular centrally P‐ANCA. Perinuclear Imm. fluoroscent accentuated Imm.fluoroscent pattern‐ pattern‐ MPO Cleveland clinic journal of Medicine Supp.3,V 79, Nov.2012 PR3 GPA MPA EGPA ENT Necrotizing None Allergic Lung Nodule, Cavity, Infiltrate Allergy, Asthma Infiltrate Kidney ++++ ++++ ++ Nerve ++ +++ ++++ Granuloma +++++ None ++++ Eosinophil None None ++++ Skin ++ ++++ ++++ ANCA 80‐95% PR3 40‐80% MPO 40% MPO 5‐20% MPO 35% PR3 35% PR3 0‐20% negative 0‐20% negative Up to 60% negative Types of Crescentic GN in consecutive Renal Treatment of ANCA Vasculitis Biopsies in Univ. of North Carolina • Pulse steroids 1 GM daily for 3 days followed by Prednisone 1 mg / Kg daily • Cyclophosphamide or Rituximab • Plasmapheresis • Diffuse Alveolar hemorrhage • Severe Renal failure RPGN Type I: Goodpasture’s Syndrome RPGN Type I: Goodpasture’s Syndrome • Anti‐GBM antibody‐induced disease. The anti‐GBM antibodies cross‐ react with pulmonary alveolar • Cells accumulate in Bowman’s space, form crescents. basement membranes to produce the clinical picture of • The Goodpasture antigen is a peptide within the pulmonary hemorrhage noncollagenous portion of the α3‐chain of associated with renal failure. collagen type IV. • What triggers the formation of these antibodies is unclear • There is linear deposition of antibodies and complement components along the GBM. 5 11/6/2016 Frequency of crescents in different types of glomerular Treatment of Good Pastures Syndrome diseases in University of North Carolina. Kidney International, Vol 63 (2003) pp.1164‐1177 Numbers % with any % with >50% Average %of • Plasmapheresis daily ASAP crescents crescents crescents Anti‐GBM 105 97.1 84.8 77 ANCA GN 181 89.5 50.3 49 • Pulse Steroids 1 GM daily for 3 days and then 1 Lupus‐III & IV 784 56.5 12.9 31 mg / Kg daily HSP 31 61.3 9.7 27 IgA 853 32.5 4 21 Post‐infectious 120 33.3 3.3 19 • Cyclophosphamide IV or PO Type I MPGN 307 23.8 4.6 25 Type II MPGN 16 43.8 18.8 48 Fibrillary GN 101 22.8 5 26 Mon. Ig dep. dx 54 5.6 0 13 TMA 251 5.6 0.9 20 Membranous 1092 3.2 0.1 15 RPGN IgA nephropathy Which type of glomerulonephritis usually do not present as RPGN ? Autoimmune systemic disease –kidneys are A. IgA nephritis bystanders B. Lupus nephritis C. Fibrillary GN Defective glycosylation of IgA1 fraction with with D. FSGS galactose deficiency 75% of patients with IgA nephropathy has galactose deficient IgA1 level above 90th percentile Glomerular and tubular injury by immune complexes containing containing pathogenic IgA1 Watt Rj, Julian BA, New Eng. J Med 2013;368;2402‐2414 6 11/6/2016 IgA Nephropathy Clinical outcome of IgA nephropathy • Variable clinical course • In USA IgA nephropathy is the commonest • 96% 20 years renal survival if risk factors are glomerular disease absent • In adults 1 case per 100,000 • Risk factors for dialysis or death are • In children 0.5 case per 100,000 – Urine protein > 1GM • 10 times more common in Japan – Hypertension BP > 140/90 – Severity of the histologic lesion – Reduced renal function at the time of diagnosis • N Engl J Med 2013; 368:2402‐2414 Treatment of IgA Nephropathy Rx of IgA with rapidly declining GFR KDIGO: Kidney Int Suppl 2012;2:S209‐S217 Recommendation: • Steroid + Cyclophosphamide for crescentic IgA • ACEI/ARB if urine protein 0.5 to 1gm/day (>50% glomeruli with crescents) with rapid • 6 month of steroids If urine protein > 1 gm after 3‐6m of ACEI/ARB and GFR > 50 deterioration in GFR • Fish oil • Supportive care if kidney biopsy shows acute BP Target: tubular injury and intratubular erythrocyte casts • <130/80 if urine protein <1 g/day but <125/75 if >1 g/day Rx of IgA without proven benefit Case: In Hospital KDIGO: Kidney Int Suppl 2012;2:S209‐S217 49 YO W obese male with DM & HTN is admitted with fever, • Steroids + Cyclophosphamide or Azathioprine, unless chronic diabetic foot ulcer complicated by MRSA osteomyelitis. crescentic IgA with rapid decline in GFR He became hypotensive and dehydrated but now improved with IVFs. He is on vancomycin. He received IV contrast 10 days • Immunosuppressive Rx with GFR of <30 unless ago for a CT scan. crescentic IgA nephropathy with rapid decline in GFR Exam is unremarkable except bandaged Rt foot and bilateral • MMF lower extremities edema. • Antiplatelet agents Labs: Creatinine 2.8 ( was 1.3 6 days ago), Serum albumin 2.9, • Tonsillectomy C3 is low but C4 normal. UA: ++ protein on dip and 23 RBC / HPF 7 11/6/2016 Case: In Hospital Infection related

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    9 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us